BRIEF published on 07/24/2025 at 14:16, 4 months 11 days ago FUTRUE GmbH Proposes Squeeze-Out for PharmaSGP Minority Shareholders Shareholders Compensation Squeeze-out PharmaSGP Futrue GmbH
PRESS RELEASE published on 07/24/2025 at 14:11, 4 months 11 days ago EQS-Adhoc: FUTRUE GmbH submits request to implement squeeze-out of minority shareholders of PharmaSGP Holding SE FUTRUE GmbH requests squeeze-out of minority shareholders by PharmaSGP Holding SE as it holds over 95% shares. Valuation ongoing for cash compensation determination Squeeze-out Minority Shareholders Cash Compensation PharmaSGP Holding SE Futrue GmbH
BRIEF published on 07/18/2025 at 12:02, 4 months 17 days ago PharmaSGP Holding SE Announces Delisting Offer by FUTRUE GmbH Shareholders Healthcare Products Delisting Offer PharmaSGP Futrue GmbH
PRESS RELEASE published on 07/18/2025 at 11:57, 4 months 17 days ago PharmaSGP Holding SE: Acceptance period for FUTRUE GmbH’s public delisting tender offer underway PharmaSGP Holding SE announces FUTRUE GmbH's public delisting tender offer acceptance period. Shareholders can tender shares for €28.00 cash consideration until August 11, 2025 Shareholders Tender Offer Delisting Cash Consideration PharmaSGP Holding SE
BRIEF published on 07/11/2025 at 08:06, 4 months 24 days ago PharmaSGP Holding SE Revises 2025 Revenue Forecast Adjusted EBITDA Revenue Adjustment PharmaSGP 2025 Forecast Geopolitical Uncertainty
PRESS RELEASE published on 07/11/2025 at 08:01, 4 months 24 days ago EQS-Adhoc: PharmaSGP Holding SE adjusts its revenues forecast for the full year 2025 PharmaSGP Holding SE adjusts full year 2025 revenue forecast due to current data evaluation. Adjusted forecast now €132.0-138.0 million. EBITDA expectation maintained EBITDA Revenue Forecast PharmaSGP Holding SE Adjusted Forecast 2025 Fiscal Year
BRIEF published on 06/26/2025 at 12:44, 5 months 8 days ago PharmaSGP Holding SE Holds Annual General Meeting 2025 Financial Results Dividend Policy Annual Meeting PharmaSGP 2025 Forecast
PRESS RELEASE published on 06/26/2025 at 12:39, 5 months 8 days ago PharmaSGP Holding SE holds 2025 Annual General Meeting PharmaSGP Holding SE reports on 2025 Annual General Meeting, with 91.12% share capital represented, €0.05 dividend per share approved, and confirmation of 2025 fiscal year forecast Annual General Meeting Dividend Forecast PharmaSGP Holding SE OTC Pharmaceuticals
BRIEF published on 06/18/2025 at 17:34, 5 months 16 days ago PharmaSGP SE to Redeem Shares Amid Upcoming Delisting Treasury Shares Delisting Squeeze-out Share Redemption PharmaSGP
PRESS RELEASE published on 06/18/2025 at 17:29, 5 months 16 days ago PharmaSGP SE plans to redeem own shares – conditions for squeeze-out under conversion law are met PharmaSGP SE plans to redeem treasury shares to optimize use of new authorization, leading to a squeeze-out possibility due to increased ownership percentage Share Buyback Treasury Shares Squeeze-out PharmaSGP Conversion Law
Published on 12/05/2025 at 02:35, 3 hours 38 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 13 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 8 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 13 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 43 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 22 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 48 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 58 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 2 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 13 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 28 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 29 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 12 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
